Abstract: Embodiments of the present invention relate to mechanically-activated microcapsules (MAMCs) for controlled drug-delivery, wherein the MAMCs release one or more active ingredients in response to mechanical stimuli in a subject's body. The MAMCs provide a platform for stimulating biological regeneration, biological repair, modifying disease, and/or controlling disease in mechanically-loaded musculoskeletal tissues.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: Provided are localized therapeutic delivery articles, comprising: a first fibrous layer comprising a first plurality of nanofibers; and a second fibrous layer comprising a second plurality of nanofibers, the first fibrous layer and the second fibrous layer being sealed to one another so as to define at least one sealed compartment therebetween, the article optionally comprising a first population of mechanically-responsive delivery particles configured to rupture upon exposure to a first rupture force, the first population of mechanically responsive delivery particles being disposed within at least one sealed compartment. The nanofibers can be aligned, which alignment allows the layers to emulate the structure of various body tissues, thereby affording control over cell growth on the articles. Also provided are methods of using and fabricating the disclosed articles.

Abstract: A composition, comprising: a hydrogel comprising crosslinked polymer chains, at least some of the crosslinked polymer chains having an agent coupled thereto. A method, comprising curing a precursor composition so as to give rise to a composition according to the present disclosure. A precursor composition, comprising: polymer chains bearing pendant groups; a crosslinker adapted to couple pendant groups to one another; and a functionalizer adapted to couple to a pendant group. A method, comprising curing a precursor composition according to the present disclosure so as to give rise to a composition, the composition optionally being a composition according to the present disclosure. A method, comprising: forming a hydrogel; and coupling the hydrogel to an agent, the coupling being effected by coupling (1) a pendant group borne by a polymer chain of the hydrogel and (2) a coupler associated with the agent.

Abstract: Embodiments of the present invention relate to mechanically-activated microcapsules (MAMCs) for controlled drug-delivery, wherein the MAMCs release one or more active ingredients in response to mechanical stimuli in a subject's body. The MAMCs provide a platform for stimulating biological regeneration, biological repair, modifying disease, and/or controlling disease in mechanically-loaded musculoskeletal tissues.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the compounds of Formula (I) for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: A composition, comprising: a plurality of mechanically-activated microcapsules; a mechanically-activated microcapsule defining a shell and an exterior surface; and the mechanically-activated microcapsule comprising one or more adhesion groups disposed Non the exterior surface of the mechanically-activated microcapsule, the one or more adhesion groups being configured to effect a covalent interaction, a non-covalent interaction, or both between the one or more adhesion groups and a matrix material, the covalent interaction, the non-covalent interaction, or both adhering the mechanically-activated microcapsule to the matrix material. Also provided are related methods and related articles.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: Feedstocks are provided for use in the additive manufacturing of three-dimensional objects via extrusion-based techniques, such as Fused Filament Fabrication (“FFF”) or Fused Deposition Modeling (“FDM”). Generally, the feedstocks may be in the form of substantially continuous filaments and/or in the form of rods of specified length, with diameters in excess of 3.5 mm.

Abstract: The invention relates to methods for the treatment or prevention of anaemia of inflammation comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of an inhibitor of the Ca2+-activated potassium channel (Gardos channel), an inhibitor of interaction of one or more chemokines with Duffy antigen receptor for chemokines (DARC), and a compound that inhibits activation of adhesion molecules expressed on erythrocytes.

Abstract: A light guide has an elongated body that includes an entrance face at which light is admitted into the light guide and an exit face at which the light emanates from the light guide. The light guide has an inboard side wall and an outboard side wall extending between the entrance face and the exit face. The entrance face, the exit face, the inboard side wall and the outboard side wall enclose a medium containing a colorant by which the medium meets a color criterion while minimizing light absorption at a wavelength of the light.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the compounds of Formula (I) for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention pertains to a lighting device for an automobile comprising a housing, a plurality of light sources arranged inside the housing and an optical element arranged in front of the plurality of light source. The optical element includes an input surface, an output surface and a transparent portion that is disposed between the input surface and the output surface. In addition, the optical element includes at least one part of the transparent portion having a blocking portion that is created using a laser treatment. The blocking portion is configured to block at least a part of the plurality of light beams from passing through the optical element.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The disclosure provides methods of treating cancer in a subject or preventing a relapse or reducing the incidence of relapse of cancer in a subject in remission, comprising administering to the subject: (a) a therapeutically effective amount of an immunotherapeutic agent, e.g., an immune checkpoint blockade therapy, an adoptive cellular therapy, a marrow-infiltrating lymphocytes, an adenosine A2aR inhibitor, or an antibody; and (b) a compound having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).

Abstract: A monitoring system that is configured to monitor a property is disclosed. The monitoring system includes a sensor that is configured to generate sensor data that reflects an environmental condition of the property and an electrical monitoring device coupled to an electrical cord that provides power to an electrical device located at the property. The electrical monitoring device is configured to generate electrical data that reflects electricity that flows through the electrical cord. The monitoring system includes a monitor control unit that is configured to: receive, from the sensor, the sensor data; receive, from the electrical monitoring device, the electrical data; and analyze the sensor data and the electrical data. The monitor control unit is configured to: based on analyzing the sensor data and the electrical data, determine a status of the electrical device; and based on the status of the electrical device, perform a monitoring system action.

Abstract: A circuit for direct current (DC) offset estimation comprises a quantile value circuit and a signal processor. The quantile value circuit determines a plurality of quantile values of an input signal and includes a plurality of quantile filters. Each quantile filter includes a comparator, a level shifter, a monotonic transfer function component, and a latched integrator. The comparator compares the input signal and a quantile value. The level shifter shifts the output of the comparator. The monotonic transfer function component determines the magnitude of the shifted signal and provide a transfer function signal. The latched integrator suppresses transient characteristics of the transfer function signal and provide the quantile value. The signal processor is configured to calculate a weighted average of the quantile values to yield a DC offset estimate.

Abstract: In an example, a method is performed by a computing system that is one of a group of computing systems involved in facilitating a manufacturing of an aircraft. The method comprises generating a plurality of manufacturing task work statements (MTWSs), each MTWS being associated with a task involved in the manufacturing and comprising smart contract data and computer code. The method also comprises receiving system state information indicating (i) a schedule according to which the aircraft is to be manufactured, (ii) resources available for use in executing the MTWSs, and (iii) one or more aircraft certification requirements with which the tasks involved in the manufacturing of the aircraft are to comply. The method also comprises executing the MTWSs based on the system state information and storing, in a blockchain-based distributed ledger accessible by the group of computing systems, an end state result of the execution of each MTWS.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.